Ocera Therapeutics Finds $14.5M

San Diego-based Ocera Therapeutics, a new company focused on biopharmaceuticals for the treatment of gastrointestinal and liver disease, said this morning that it has raised $14.5M in a Series A funding. The funding came from Domain Associates and Thomas, McNerney and Partners. The company said that it has licensed its leading clinical candidate to Kureha Corp. in Japan and filed and IND with the FDA. The firm will use the funding to initiate clincal trails for the treatment of Crohn's disease. More information »